Clinical Trial

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provide clinical evidence for the application of dual orexin receptor antagonists in the treatment of Parkinson's Disease.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Not Yet Recruiting 2026-06-12
Trial Details
NCT Number NCT07384429
Lead Sponsor YangPan
Collaborators: Eisai China Inc., Nanjing University
Conditions Parkinson's Disease, Insomnia, Motor Disorder
Enrollment 44 participants
Start Date 2026-08-19
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-11